全文获取类型
收费全文 | 350篇 |
免费 | 5篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 4篇 |
基础医学 | 116篇 |
口腔科学 | 5篇 |
临床医学 | 19篇 |
内科学 | 98篇 |
神经病学 | 17篇 |
特种医学 | 7篇 |
外科学 | 46篇 |
综合类 | 1篇 |
预防医学 | 2篇 |
眼科学 | 4篇 |
药学 | 14篇 |
中国医学 | 1篇 |
肿瘤学 | 22篇 |
出版年
2022年 | 1篇 |
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 3篇 |
2017年 | 5篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2014年 | 6篇 |
2013年 | 8篇 |
2012年 | 8篇 |
2011年 | 10篇 |
2010年 | 15篇 |
2009年 | 10篇 |
2008年 | 31篇 |
2007年 | 37篇 |
2006年 | 31篇 |
2005年 | 36篇 |
2004年 | 24篇 |
2003年 | 31篇 |
2002年 | 28篇 |
2001年 | 13篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 5篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 6篇 |
1993年 | 5篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1986年 | 1篇 |
1981年 | 1篇 |
1980年 | 3篇 |
排序方式: 共有356条查询结果,搜索用时 15 毫秒
351.
Kojima M Itoh H Shimizu K Saruki N Murayama K Higuchi K Tamaki Y Matsumoto M Hirabayashi K Igarishi S Masawa N Nakamura S 《International journal of surgical pathology》2006,14(1):43-48
We conducted clinicopathologic and immunohistochemical analyses of the prevalence of Epstein-Barr virus (EBV) among 24 patients with malignant lymphoma complicating systemic rheumatic diseases. (SRD) These 24 patients included 17 with rheumatoid arthritis (RA), 3 with systemic lupus erythematosus (SLE), 2 with systemic sclerosis (SS), and 2 with dermatomyositis (DM). There were 2 men and 22 women ranging in age from 30 to 86 years (mean: 64 years). The interval between the onset of rheumatic disease and that of malignant lymphomas ranged from 3 months to 35 years (mean: 142 months). The use of immunosuppressive drugs before the onset of malignant lymphoma was recorded in 15 patients. Among them, 5 patients received methotrexate (MTX) therapy. Malignant lymphomas were found at extranodal sites in 9 patients, and the disease was in the advanced stage in 17 patients. Histologic and immunohistochemical studies demonstrated that 18 cases (75%) were B-cell lymphoma (RA=12, SLE=2, SS=2, DM=2), 3 (12.5%) were peripheral T-cell lymphoma (RA=3), and 3 (12.5%) were classical Hodgkin lymphoma (RA=2, SLE=1). As in previous reports, there was an increased frequency of diffuse large B-cell lymphoma (50%) in the present series. Moreover, a majority of the diffuse large B-cell lymphomas exhibited activated B-cell phenotype. EBV-encoded small RNAs (Epstein-Barr early region [EBER]-) and/or LMP-1+tumor cells were identified in only 3 cases of classical Hodgkin lymphomas. Our findings suggested EBV-associated lymphoma comprised only a small fraction of all non-Hodgkin's lymphomas in the general SRD patient population. 相似文献
352.
Shigenobu Matsumura Ai EguchiTakafumi Mizushige Nobuhide KitabayashiSatoshi Tsuzuki Kazuo InoueTohru Fushiki 《Neuroscience letters》2009
A recent study has demonstrated that the G-protein coupled receptor GPR120 is expressed in the taste bud cells in rats. In this study, we have identified the types of taste cell that express GPR120 in C57/BL6 mice. Double immunostaining for GPR120 and the markers of type II taste cells (phospholipase-Cβ2 and α-gustducin) revealed that the majority of the GPR120-positive taste cells are type II taste cells. In contrast, it was observed that GPR120 was rarely colocalized with the marker of type III cells (neuronal cell adhesion molecule). These results suggested that GPR120 is mainly expressed in the type II taste cells and might function as a sensor for dietary fat. 相似文献
353.
A 55-year-old man was hospitalized for treatment of a giant, fluid-filled bulla in the upper lobe of the right lung. The infection
was resistant to antibiotics, and the resulting drug-induced liver dysfunction prohibited us from performing emergency lobectomy.
Percutaneous drainage of the bulla was done initially, using a 28-Fr chest tube, after which the symptoms of infection improved
rapidly. Despite a small air leakage, which became evident on day 4 of drainage, shrinkage of the bulla was achieved, and
elective bullectomy was performed after continuous drainage for 21 days. Thus, percutaneous drainage was effective in controlling
the infection and minimizing the invasiveness of surgery. 相似文献
354.
Yoshida K Sugiura T Takifuji N Kawahara M Matsui K Kudoh S Takada M Fukuoka M Ariyoshi Y Fukuda H Saijo N 《Lung cancer (Amsterdam, Netherlands)》2007,58(3):362-368
To evaluate the efficacy and toxicity of three intrapleural therapy regimens consisting of bleomycin (BLM), OK-432 (a pulverized product of heat-killed Streptococcus pyogenes) or cisplatin plus etoposide (PE) for the management of malignant pleural effusion (MPE) in previously untreated non-small cell lung cancer. Eligible patients were randomized to the BLM arm: BLM 1mg/kg (maximum 60mg/body), the OK-432 arm: OK-432 0.2 Klinische Einheit units (KE)/kg (maximum 10KE/body), or the PE arm: cisplatin (80mg/m(2)) and etoposide (80mg/m(2)). Pleural response was evaluated every 4 weeks according to the study-specific criteria. All responders received systemic chemotherapy consisting of PE every 3-4 weeks for two or more courses. Pleural progression-free survival (PPFS) was defined as the time from randomization to the first observation of pleural progression or death due to any cause. The primary endpoint was the 4-week PPFS rate. Of 105 patients enrolled, 102 were assessed for response. The 4-week PPFS rate for the BLM arm was 68.6%, 75.8% for the OK-432 arm, and 70.6% for PE arm. Median survival time (MST) for the BLM arm was 32.1 weeks, 48.1 weeks for the OK-432 arm, and 45.7 weeks for the PE arm. However, the outcomes did not differ significantly between groups. Toxicity was tolerable in all arms except for one treatment-related death due to interstitial pneumonia induced by BLM. We will select intrapleural treatment using OK-432 in the management of MPE in NSCLC for further investigation because it had the highest 4-week PPFS rate. 相似文献
355.
356.
BACKGROUND: Insulin measurement is used for the diagnosis of hypoglycemia and for insulin pharmacokinetic evaluations. We assessed the analytical and clinical performance of the ARCHITECT insulin assay, a chemiluminescent immunoassay recently introduced for the ARCHITECT i2000 fully automated immunoassay analyzer (Abbott Laboratories). We also tested whether major insulin analogs cross-reacted with the immunoassay reagents. METHODS: We used Clinical and Laboratory Standards Institute protocols to assess the analytical performance of the ARCHITECT insulin assay and compared its accuracy with that of the E-test TOSOH II (IRI) from TOSOH Corporation. We used 3 recombinant insulin analogs (lispro, aspart, and glargine) to evaluate the cross-reactivity of insulin analogs with the ARCHITECT immunoassay reagent. RESULTS: The total CV for the ARCHITECT assay was < 5%. Correlation between the ARCHITECT insulin assay and the E-test TOSOH II (IRI) was satisfactory in the measured range, but we detected a slope deviation between the assays. The ARCHITECT insulin assay showed low cross-reactivity to the insulin analog aspart, whereas it detected the other insulin analogs, lispro and glargine, in concentrations as high as the theoretical concentrations. CONCLUSIONS: The ARCHITECT insulin assay showed favorable basic performance, including reproducibility, dilution linearity, detection limit, and effects of interfering substances. When interpreting results, clinicians and laboratory pathologists should be aware of the cross-reactivity of the ARCHITECT and other immunoassays to specific insulin analogs prescribed to diabetes patients. 相似文献